Skip to main content

Table 2 Efficacy at day 28, day 42 and day 56 (trial 1 only) expressed as percentage with ACPR

From: Clinical trials of artesunate plus sulfadoxine-pyrimethamine for Plasmodium falciparum malaria in Afghanistan: maintained efficacy a decade after introduction

  DP AS + SP T1 AS + SP T2 AS + SP T3
N (enrolled) 59 61 100 83
d28
 Successful follow-up 53 57 97 78
 Reinfection 0 0 0 0
 Analysed 53 57 97 78
 Recrudescence 0 0 1 0
 ACPR % (95 % CI) 100 (93.2–100) 100 (93.7–100) 99.0 (94.4–99.8) 100 (95.3–100)
d42
 Successful follow-up 52 56 97 77
 Recurrence: reinfection 0 0 3 1
 Recurrence: unknown genotype 0 0 2 0
 Analysed 52 56 92 76
 Recrudescence 0 0 2 0
 ACPR (95 % CI) 100 (93.1–100) 100 (93.6–100) 97.8 (92.4–99.4) 100 (95.2–100)
d56
 Successful follow-up 50 52   
 Recurrence: reinfection 0 0   
 Recurrence: unknown genotype 0 0   
 Analysed 50 52   
 Recrudescence 0 0   
 ACPR (95 % CI) 100 (92.9–100) 100 (93.1–100)   
  1. Successful follow-up indicates patients seen up to and including the corresponding time point. Recurrences due to reinfection and one patient in the AS + SP arm with P. vivax infection at d28 were censored from analysis